AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Absci Corporation (ABSI)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

5.20

-0.37 (-6.64%)

At close: Feb 20, 2025, 3:59 PM

5.17

-0.48%

After-hours: Feb 20, 2025, 06:37 PM EST

undefined% (undefined)

Bid	5.17
Market Cap	596.68M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.93
PE Ratio (ttm)	-5.59
Forward PE	n/a
Analyst	Buy

Ask	5.2
Volume	4,346,047
Avg. Volume (20D)	4,926,457
Open	5.50
Previous Close	5.57
Day's Range	5.05 - 5.51
52-Week Range	2.45 - 6.72
Beta	undefined

About ABSI

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington....

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 22, 2021

Employees 155

Stock Exchange NASDAQ

Ticker Symbol ABSI

Website https://www.absci.com

Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for ABSI stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 73.24% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Absci Corporation is scheduled to release its earnings on Mar 20, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+25.16%

Absci shares are trading higher after Needham init... Unlock content with Pro Subscription

1 month ago

+4.89%

Abscri shares are trading higher after the company announced a strategic collaboration with AMD. Abscri will receive a $20 million investment as part of the deal.

News

1 month ago · benzinga.com

Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside

Needham analyst has initiated coverage on Absci Corporation ABSI, a drug and target discovery company that harnesses deep learning AI and synthetic biology to expand proteins' therapeutic potential.

1 month ago · seekingalpha.com

Absci Looks Cheap And Positioned For Growth With AMD's AI Backing

Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. ABS-101 appears to be ABSI's main drug candidate for IBD. However, ABS-201 for hair lo...